Translational Development Acquisition (TDAC) Net Income towards Common Stockholders (2024 - 2026)

Translational Development Acquisition (TDAC) has 3 years of Net Income towards Common Stockholders data on file, last reported at $283351.0 in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 75.74% year-over-year to $283351.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $468218.0 (down 59.78% YoY) and the FY2025 annual result came in at $1.4 million, up 25392.48% from the prior year.
• Net Income towards Common Stockholders advanced to $283351.0 in Q1 2026, from -$2.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.3 million in Q3 2025 to a low of -$2.4 million in Q4 2025.
• A 3-year average of $233190.0 and a median of $283351.0 in 2026 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 2233.03% in 2025, down 4266.15% in 2025.
• Tracing TDAC's Net Income towards Common Stockholders over 3 years: stood at $57620.0 in 2024, then sank by 4266.15% to -$2.4 million in 2025, then surged by 111.8% to $283351.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at $283351.0 (Q1 2026), -$2.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.